Title: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Journal: Drugs20170701
Title: Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Journal: The New England journal of medicine20170601
Title: In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
Journal: Antiviral therapy20170101
Title: Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Journal: The Annals of pharmacotherapy20160101
Title: Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C.
Journal: Journal of virus eradication20160101
Title: Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance.
Journal: Viruses20151001
Title: Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver20150901
Title: Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Journal: The New England journal of medicine20150820
Title: Hepatitis C virus: Virology, diagnosis and treatment.
Journal: World journal of hepatology20150608
Title: Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.
Journal: Clinical therapeutics20150501
Title: Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.
Journal: Expert opinion on pharmacotherapy20150401
Title: Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
Journal: Drugs20150401
Title: Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Journal: Lancet (London, England)20150321
Title: Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
Journal: JAMA20150301
Title: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
Journal: Canadian journal of gastroenterology & hepatology20150101
Title: Changing the face of hepatitis C management - the design and development of sofosbuvir.
Journal: Drug design, development and therapy20150101
Title: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Journal: BMC gastroenterology20150101
Title: Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase.
Journal: Antimicrobial agents and chemotherapy20140701
Title: The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Journal: Antimicrobial agents and chemotherapy20140601
Title: Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.
Journal: Antimicrobial agents and chemotherapy20140501
Title: Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase.
Journal: Journal of medicinal chemistry20140313
Title: Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
Journal: Hepatology (Baltimore, Md.)20140201
Title: Sofosbuvir for the treatment of hepatitis C virus.
Journal: Expert opinion on pharmacotherapy20140101
Title: Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.
Journal: Antimicrobial agents and chemotherapy20130301
Title: Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.
Journal: Antimicrobial agents and chemotherapy20120601
Title: Interferon free hepatitis C treatment regimens: the beginning of another era.
Journal: Current gastroenterology reports20120201
Title: Treatment of chronic hepatitis C--are interferons really necessary?
Journal: Liver international : official journal of the International Association for the Study of the Liver20120201
Title: What's new in HCV genotype 2 treatment.
Journal: Liver international : official journal of the International Association for the Study of the Liver20120201
Title: Trial watch: an all-oral and interferon-free future for HCV therapy?
Journal: Nature reviews. Drug discovery20111201
Title: Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938.
Journal: Nucleosides, nucleotides & nucleic acids20111101
Title: Synthesis of diastereomerically pure nucleotide phosphoramidates.
Journal: The Journal of organic chemistry20111021
Title: The HCV NS5B nucleoside and non-nucleoside inhibitors.
Journal: Clinics in liver disease20110801
Title: Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.
Journal: The Journal of biological chemistry20101105
Title: Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
Journal: Journal of medicinal chemistry20101014
Title: Genetic diversity and evolution of hepatitis C virus--15 years on.
Journal: The Journal of general virology20041101
Title: Side effects of alpha interferon in chronic hepatitis C.
Journal: Hepatology (Baltimore, Md.)19970901
Title: Murakami E, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem. 2010 Nov 5;285(45):34337-47.
Title: Lam AM, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68.
Title: Sofia MJ, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010 Oct 14;53(19):7202-18.
Title: Zhang X, et al. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. Eur J Med Chem. 2018 Jan 1;143:1053-1065.
